Clinical Trials Browser

Active not recruiting × INDUSTRY × ibrutinib × Clear all

NCT03960840 2026-04-17

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03462719 2026-04-13

GLOW

Phase 3 Active not recruiting

211 enrolled 23 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02477696 2026-03-27

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Phase 3 Active not recruiting

533 enrolled 18 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Phase 2 Active not recruiting

LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

NCT03229200 2025-10-30

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Phase 4 Active not recruiting

LymphoidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

NCT04662255 2025-05-28

BRUIN-MCL-321

Phase 3 Active not recruiting

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT03379428 2024-12-06

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms